An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematolo
The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardize
| Condition(s) | Lymphoma, Multiple Myeloma |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | The goal of this study is to evaluate the feasibility and preliminary efficacy of an artificial intelligence (AI)-generated personalized question prompt list (a list of suggested questions to ask during outpatient appointments) for patients with hematologic cancers. The intervention will involve tailoring a standardized prompt to patients' individual characteristics and concerns. This prompt will then be used to ask Washington University's (WashU) HIPAA compliant ChatGPT to generate personalized question lists for outpatient appointments. Analyses will assess the impact of personalized QPLs on patients' question-asking behavior; communicative self-efficacy; and self-reported amount and satisfaction with information obtained about their disease and its treatment. Sub-analyses will explore p |
| Who can participate | Eligibility Criteria as determined by Electronic Health Record (EHR) Screening: * Documented diagnosis of lymphoma, as defined by ICD-10 codes C81-C88 or multiple myeloma, as defined by ICD codes C90.0-C90.02 * Has a scheduled follow-up appointment at a participating outpatient oncology clinic within the next month. Participating clinics include: * Dr. David Russler-Germain: Outpatient Lymphoma Clinic * Dr. Michael Slade: Outpatient Multiple Myeloma Clinic * Dr. Dilan Patel: Outpatient Lymphoma Clinic * Undergoing infusion or injection-based systemic therapy intended to cure or manage the disease, as opposed to regimens delivered solely for palliative purposes, at a frequency of once every 1-4 weeks. * For eligible patients with lymphoma, this includes, but is not limited to, commonly pres |
| Ages | 18 Years to 99 Years |
| Sex | All |
| Lead sponsor | Washington University School of Medicine |
| Locations | St Louis, Missouri, United States |
| Start date | 2025-12-26 |
| NCT ID | NCT07226934 |
| Official listing | https://clinicaltrials.gov/study/NCT07226934 |